Long-term effect of denosumab on bone microarchitecture as assessed by tissue thicknessadjusted Trabecular Bone Score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension
Abstract:
Summary: In postmenopausal women with osteoporosis, up to 10 years of denosumab treatment significantly and continuously improved bone microarchitecture assessed by tissue thicknessadjusted trabecular bone score, independently of bone mineral density.
Long-term denosumab treatment decreased the number of high fracture-risk patients and shifted more patients to lower fracture-risk categories.
Purpose: To investigate the long-term effect of denosumab on bone microarchitecture assessed by tissue thicknessadjusted trabecular bone score (TBS TT) in post-hoc subgroup analysis of FREEDOM and open-label extension (OLE).
Methods: Postmenopausal women with lumbar spine (LS) or total hip BMD T-score
